Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Mar 02,2022
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
On February 22, Shanghai Medicilon Inc (Medicilon)'s partner Imbioray (Hangzhou) Biomedicine Co., Ltd. (Imbioray) announced the completion of RMB 230 million Round A financing.
More
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
Feb 28,2022
Medicilon Won Praise and Awards From Many Partners
Leading Tac Pharma's PROTAC drug project is a first-in-class research and development project that challenges anti-tumor and autoimmune diseases. In the cooperation with Medicilon, the Medicilon's DMPK team actively communicated with Leading Tac which helped customers solve a series of research and development problems such as large molecular weight, ensuring the completion of the project.
More
Medicilon Won Praise and Awards From Many Partners
Feb 18,2022
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Zhenrong Guo as the Executive Vice President of VCMC(APIs + Preparations).
More
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Feb 17,2022
World's First Inhaled Nanobody Drug LQ036
In the development process of the world's first inhaled nanobody drug for the treatment of moderate and severe asthma, Medicilon assists LQ036 to complete the quality research services of inhaled preparations.
More
World's First Inhaled Nanobody Drug LQ036
Jan 27,2022
Happy Chinese New Year!
Happy Chinese New Year!
More
Happy Chinese New Year!
Jan 24,2022
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
On December 28, 2021, Hangzhou DAC Biotechnology Co., Ltd. (DAC Biotech) DXC007 project was successfully approved for clinical trials. DXC007 is the fourth ADC drug approved for clinical use by DAC Biotech, and it is also the fourth ADC drug that Shanghai Medicilon Inc. (Medicilon) to help DAC Biotech successfully getting approval.
More
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
More
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Jan 10,2022
Bao Pharmaceutical and Medicilon reached a strategic collaboration
On December 17, 2021, Shanghai Bao Pharmaceutical Co., Ltd. (Bao) and Shanghai Medicilon Inc. (Medicilon) signed an innovative drug IND R&D service strategy collaboration agreement.
More
Bao Pharmaceutical and Medicilon reached a strategic collaboration
Jan 04,2022
Recording the Growth of Medicilon in 2021
This year, Medicilon, with persistent belief, courageously and innovatively, pursued quality, and gave birth to the power of joint growth. Today, we take you to review the 2021 and witness the growth and progress of Medicilon!
More
Recording the Growth of Medicilon in 2021
Dec 20,2021
Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
On December 20, China Securities Journal announced the list of the 23rd (2020) "Golden Bull Awards" for listed companies. Shanghai Medicilon Inc. (Medicilon) won the 2020 "Golden Bull Science and Technology Innovation Award."
More
Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
Nov 24,2021
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Recently, the "2021 Yangpu Service Trade Digital Transformation Forum” under the guidance of the Shanghai Municipal Commission of Commerce and the People's Government of Yangpu District was grandly held.
More
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Nov 24,2021
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
On November 16, the "2021 Jiemian Health Forum” hosted by Shanghai United Media Group and Jiemian News was successfully held.  As a major part of
More
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->